The company conducts much of its business in the United States and will benefit from the current strength of the US dollar against the euro. According to Sanofi's preliminary estimates, currency movements alone are expected to increase Q4 sales by 4.5%-5.5% and positively impact 6%-7% on the company's Q4 core earnings per share.
Sanofi's Q4 Results to be Published in Early February
Sanofi's Q4 results, published in early February, are anticipated to reflect the positive impact of foreign exchange movements and flu vaccine sales. The company, which conducts a significant portion of its business in the United States, will benefit from the strength of the US dollar against the euro.
Sanofi's preliminary estimates show that currency movements alone are expected to boost Q4 sales by 4.5%-5.5% and positively impact 6%-7% on the company's Q4 core earnings per share.
